EYP-1901 vs Aflibercept for DME

(DME Trial)

This trial tests two treatments, EYP-1901 and Aflibercept, to determine which better treats diabetic macular edema (DME), a condition where fluid accumulates in the retina, causing vision problems. The study aims to assess whether the new treatment, EYP-1901 (an experimental treatment), is more effective than the existing one, Aflibercept. Individuals with diabetic retinopathy and retinal swelling, regardless of prior treatment, may be suitable candidates. This includes those who have received at least one injection for DME in the last year but not in the past three months. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment.

The trial information does not specify if you need to stop taking your current medications. However, if you have received anti-VEGF treatment for DME, it must have been at least 12 weeks before the screening visit.

Research has shown that EYP-1901 is generally well-tolerated by patients. In several studies, including those for diabetic macular edema (a condition where fluid builds up in the eye), EYP-1901 demonstrated a good safety record. No serious side effects were linked to the drug, either in the eye or elsewhere in the body. This suggests that EYP-1901 is safe to use, at least in the clinical trials conducted so far.

Researchers are excited about EYP-1901 for diabetic macular edema (DME) because it offers a new approach compared to existing treatments like Aflibercept. Unlike standard treatments that typically require frequent injections, EYP-1901 is designed to be administered less often, potentially improving patient compliance and convenience. Additionally, EYP-1901 utilizes a unique mechanism by delivering a sustained release of a tyrosine kinase inhibitor, which targets pathways involved in abnormal blood vessel growth and leakage, providing a new angle in managing DME. This innovative delivery system and mechanism could lead to lasting improvements for patients with fewer visits to the doctor.

This trial will compare EYP-1901 with Aflibercept for treating diabetic macular edema (DME). Research has shown that EYP-1901 can effectively treat DME, a condition affecting the eyes. In one study, 40% to 50% of patients who received EYP-1901 no longer had DME after 24 weeks, while none in the Aflibercept group experienced this improvement. Additionally, patients maintained stable vision, and the thickness of the central part of their retina remained consistent for six months after just one dose of EYP-1901. This suggests that EYP-1901 may offer a long-lasting benefit for managing DME.³⁵⁶⁷⁸